ADCT
ADC Therapeutics SA
Price Chart
Latest Quote
$3.90
Current Price| Previous Close | $3.61 |
| Open | $3.58 |
| Day High | $3.99 |
| Day Low | $3.59 |
| Volume | 651,627 |
Stock Information
| Shares Outstanding | 123.88M |
| Total Debt | $457.44M |
| Cash Equivalents | $234.74M |
| Revenue | $75.21M |
| Net Income | $-166.94M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $483.12M |
| EPS (TTM) | $-1.41 |
| Exchange | NYQ |
đ Custom Metrics & Score
Score: 17/42| Debt to Equity | -0.61 |
| Debt to Earnings | 1.90 |
| Current Ratio | 3.82 |
| Quick Ratio | 3.37 |
| Avg Revenue Growth | 27.21% |
| Profit Margin | -222.83% |
| Return on Equity | 77.89% |
| Avg FCF Growth | -12.00% |
| FCF Yield | -25.81% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $3.90 | 651,627 |
| 2026-01-30 | $3.61 | 754,500 |
| 2026-01-29 | $3.76 | 746,300 |
| 2026-01-28 | $3.54 | 1,389,600 |
| 2026-01-27 | $3.59 | 659,500 |
| 2026-01-26 | $3.62 | 613,000 |
| 2026-01-23 | $3.61 | 758,300 |
| 2026-01-22 | $3.80 | 501,400 |
| 2026-01-21 | $3.57 | 1,087,800 |
| 2026-01-20 | $3.52 | 357,800 |
| 2026-01-16 | $3.62 | 754,200 |
| 2026-01-15 | $3.55 | 491,100 |
| 2026-01-14 | $3.71 | 553,200 |
| 2026-01-13 | $3.70 | 504,200 |
| 2026-01-12 | $3.82 | 898,000 |
| 2026-01-09 | $3.66 | 637,700 |
| 2026-01-08 | $3.57 | 382,800 |
| 2026-01-07 | $3.65 | 819,100 |
| 2026-01-06 | $3.54 | 818,800 |
| 2026-01-05 | $3.56 | 645,300 |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
đ° Latest News
Has ADC Therapeutics (ADCT) Outpaced Other Medical Stocks This Year?
Zacks âĸ 2026-01-30T14:40:03Z
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Zacks âĸ 2026-01-13T14:40:03Z
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why
Zacks âĸ 2025-12-29T17:00:03Z
RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development
Insider Monkey âĸ 2025-12-18T06:14:54Z
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-12-17T14:40:05Z
ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy?
Zacks âĸ 2025-12-15T17:00:05Z
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma
TipRanks âĸ 2025-12-04T12:40:45Z
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2025-12-01T14:40:04Z
ADC Therapeutics (ADCT) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2025-11-18T17:00:04Z
ADC Therapeutics SA (ADCT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Revenue ...
GuruFocus.com âĸ 2025-11-10T21:01:21ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $5,949,000 | $2,529,000 | $3,301,000 | $1,393,000 |
| Cost Of Revenue | $5,949,000 | $2,529,000 | $3,301,000 | $1,393,000 |
| Total Revenue | $70,837,000 | $69,558,000 | $209,908,000 | $33,917,000 |
| Operating Revenue | $70,837,000 | $69,558,000 | $209,908,000 | $33,917,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $50,211,000 | $46,325,000 | $36,731,000 | $18,340,000 |
| Total Expenses | $200,428,000 | $234,609,000 | $332,895,000 | $295,271,000 |
| Other Income Expense | $11,394,000 | $5,417,000 | $10,333,000 | $28,123,000 |
| Other Non Operating Income Expenses | $11,474,000 | $5,469,000 | $26,906,000 | $366,000 |
| Net Non Operating Interest Income Expense | $-37,939,000 | $-35,785,000 | $-34,163,000 | $-18,274,000 |
| Interest Expense Non Operating | $50,211,000 | $46,325,000 | $36,731,000 | $18,340,000 |
| Operating Expense | $194,479,000 | $232,080,000 | $329,594,000 | $293,878,000 |
| Selling And Marketing Expense | $21,442,000 | $33,006,000 | $35,752,000 | $64,780,000 |
| General And Administrative Expense | $64,467,000 | $72,882,000 | $107,742,000 | $136,242,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-157,846,000 | $-240,053,000 | $-157,128,000 | $-230,026,000 |
| Net Interest Income | $-37,939,000 | $-35,785,000 | $-34,163,000 | $-18,274,000 |
| Interest Income | $12,272,000 | $10,540,000 | $2,568,000 | $66,000 |
| Normalized Income | $-157,782,800 | $-240,011,920 | $-144,035,330 | $-261,849,442 |
| Net Income From Continuing And Discontinued Operation | $-157,846,000 | $-240,053,000 | $-157,128,000 | $-230,026,000 |
| Total Operating Income As Reported | $-130,654,000 | $-165,986,000 | $-123,344,000 | $-261,720,000 |
| Net Income Common Stockholders | $-157,846,000 | $-240,053,000 | $-157,128,000 | $-230,026,000 |
| Net Income | $-157,846,000 | $-240,053,000 | $-157,128,000 | $-230,026,000 |
| Net Income Including Noncontrolling Interests | $-157,846,000 | $-240,053,000 | $-157,128,000 | $-230,026,000 |
| Net Income Continuous Operations | $-157,846,000 | $-240,053,000 | $-157,128,000 | $-230,026,000 |
| Earnings From Equity Interest Net Of Tax | $-1,544,000 | $-5,528,000 | $-10,084,000 | - |
| Pretax Income | $-156,136,000 | $-195,419,000 | $-146,817,000 | $-251,505,000 |
| Interest Income Non Operating | $12,272,000 | $10,540,000 | $2,568,000 | $66,000 |
| Operating Income | $-129,591,000 | $-165,051,000 | $-122,987,000 | $-261,354,000 |
| Gross Profit | $64,888,000 | $67,029,000 | $206,607,000 | $32,524,000 |
| Special Income Charges | - | $0 | $-42,114,000 | $0 |
| Earnings From Equity Interest | - | - | $-10,084,000 | $-6,672,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.62 | $-2.94 | $-1.99 | $-3.00 |
| Basic EPS | $-1.62 | $-2.94 | $-1.99 | $-3.00 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-16,800 | $-10,920 | $-3,480,330 | $2,971,558 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-102,569,000 | $-145,775,000 | $-91,125,000 | $-265,330,000 |
| Total Unusual Items | $-80,000 | $-52,000 | $-16,573,000 | $34,795,000 |
| Total Unusual Items Excluding Goodwill | $-80,000 | $-52,000 | $-16,573,000 | $34,795,000 |
| Reconciled Depreciation | $3,276,000 | $3,267,000 | $2,388,000 | $2,630,000 |
| EBITDA (Bullshit earnings) | $-102,649,000 | $-145,827,000 | $-107,698,000 | $-230,535,000 |
| EBIT | $-105,925,000 | $-149,094,000 | $-110,086,000 | $-233,165,000 |
| Diluted Average Shares | $97,159,966 | $81,712,166 | $78,152,964 | $76,675,333 |
| Basic Average Shares | $97,159,966 | $81,712,166 | $78,152,964 | $76,675,333 |
| Diluted NI Availto Com Stockholders | $-157,846,000 | $-240,053,000 | $-157,128,000 | $-230,026,000 |
| Tax Provision | $166,000 | $39,106,000 | $227,000 | $-21,479,000 |
| Gain On Sale Of Security | $-80,000 | $-52,000 | $25,541,000 | $34,795,000 |
| Other Taxes | $-1,063,000 | $-935,000 | $-357,000 | $-366,000 |
| Research And Development | $109,633,000 | $127,127,000 | $186,457,000 | $158,002,000 |
| Selling General And Administration | $85,909,000 | $105,888,000 | $143,494,000 | $136,242,000 |
| Other Gand A | $17,683,000 | $20,542,000 | $25,985,000 | $50,303,000 |
| Salaries And Wages | $46,784,000 | $52,340,000 | $81,757,000 | $85,939,000 |
| Other Special Charges | - | - | $42,114,000 | - |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-202,642,000 | $-148,249,000 | $79,451,000 | $152,506,000 |
| Total Assets | $321,980,000 | $354,782,000 | $490,859,000 | $617,972,000 |
| Total Non Current Assets | $14,590,000 | $18,491,000 | $55,879,000 | $92,790,000 |
| Other Non Current Assets | $1,161,000 | $711,000 | $902,000 | $693,000 |
| Current Assets | $307,390,000 | $336,291,000 | $434,980,000 | $525,182,000 |
| Other Current Assets | $9,450,000 | $5,990,000 | $23,495,000 | $1,561,000 |
| Prepaid Assets | $8,370,000 | $10,344,000 | $23,296,000 | $15,350,000 |
| Inventory | $18,387,000 | $16,177,000 | $12,073,000 | $11,122,000 |
| Receivables | $20,316,000 | $25,182,000 | $72,971,000 | $32,166,000 |
| Accounts Receivable | $20,316,000 | $25,182,000 | $72,971,000 | $30,218,000 |
| Cash Cash Equivalents And Short Term Investments | $250,867,000 | $278,598,000 | $326,441,000 | $466,544,000 |
| Cash And Cash Equivalents | $250,867,000 | $278,598,000 | $326,441,000 | $466,544,000 |
| Non Current Deferred Assets | - | $0 | $37,104,000 | $26,049,000 |
| Non Current Deferred Taxes Assets | - | $0 | $37,104,000 | $26,049,000 |
| Goodwill And Other Intangible Assets | - | - | $14,360,000 | $13,582,000 |
| Other Intangible Assets | - | - | $14,360,000 | $13,582,000 |
| Other Receivables | - | - | $3,361,000 | $1,561,000 |
| Taxes Receivable | - | - | $763,000 | $387,000 |
| Accrued Interest Receivable | - | - | $619,000 | $0 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $122,998,000 | $124,377,000 | $117,375,000 | $139,698,000 |
| Long Term Debt And Capital Lease Obligation | $121,627,000 | $122,910,000 | $116,278,000 | $132,094,000 |
| Long Term Debt | $113,632,000 | $112,730,000 | $109,714,000 | $125,100,000 |
| Current Debt And Capital Lease Obligation | $1,371,000 | $1,467,000 | $1,097,000 | $7,604,000 |
| Current Debt | - | - | $12,474,000 | $6,575,000 |
| Other Current Borrowings | - | - | $12,474,000 | $6,575,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $524,622,000 | $503,031,000 | $411,408,000 | $451,884,000 |
| Total Non Current Liabilities Net Minority Interest | $444,153,000 | $435,361,000 | $329,469,000 | $377,949,000 |
| Other Non Current Liabilities | $2,433,000 | $8,879,000 | $838,000 | - |
| Non Current Deferred Liabilities | $320,093,000 | $303,572,000 | $212,353,000 | $242,203,000 |
| Current Liabilities | $80,469,000 | $67,670,000 | $81,939,000 | $73,935,000 |
| Other Current Liabilities | $26,946,000 | $13,039,000 | $16,558,000 | $14,114,000 |
| Payables And Accrued Expenses | $52,152,000 | $53,164,000 | $64,284,000 | $52,217,000 |
| Payables | $18,029,000 | $15,569,000 | $12,351,000 | $15,834,000 |
| Accounts Payable | $18,029,000 | $15,569,000 | $12,351,000 | $12,080,000 |
| Derivative Product Liabilities | - | - | $1,788,000 | $0 |
| Total Tax Payable | - | - | $0 | $3,754,000 |
| Income Tax Payable | - | - | $0 | $3,754,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $-202,642,000 | $-148,249,000 | $79,451,000 | $166,088,000 |
| Total Equity Gross Minority Interest | $-202,642,000 | $-148,249,000 | $79,451,000 | $166,088,000 |
| Stockholders Equity | $-202,642,000 | $-148,249,000 | $79,451,000 | $166,088,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,421,000 | $-93,000 | $1,823,000 | $102,829,000 |
| Other Equity Adjustments | $-1,421,000 | $-93,000 | $1,823,000 | $102,646,000 |
| Retained Earnings | $-1,493,318,000 | $-1,335,472,000 | $-1,095,419,000 | $-924,885,000 |
| Long Term Equity Investment | $0 | $1,647,000 | $7,613,000 | $41,236,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Treasury Shares Number | $2,744,974 | $6,748,809 | $8,399,419 | $1,459,522 |
| Ordinary Shares Number | $98,861,402 | $82,293,137 | $80,642,527 | $76,810,478 |
| Share Issued | $101,606,376 | $89,041,946 | $89,041,946 | $78,270,000 |
| Tangible Book Value | $-202,642,000 | $-148,249,000 | $79,451,000 | $152,506,000 |
| Invested Capital | $-89,010,000 | $-35,519,000 | $189,165,000 | $297,763,000 |
| Working Capital | $226,921,000 | $268,621,000 | $353,041,000 | $451,247,000 |
| Capital Lease Obligations | $9,366,000 | $11,647,000 | $7,661,000 | $8,023,000 |
| Total Capitalization | $-89,010,000 | $-35,519,000 | $189,165,000 | $291,188,000 |
| Treasury Stock | $220,000 | $541,000 | $679,000 | $128,000 |
| Additional Paid In Capital | $1,283,892,000 | $1,180,545,000 | $1,166,414,000 | $981,827,000 |
| Capital Stock | $8,425,000 | $7,312,000 | $7,312,000 | $6,445,000 |
| Common Stock | $8,425,000 | $7,312,000 | $7,312,000 | $6,445,000 |
| Long Term Capital Lease Obligation | $7,995,000 | $10,180,000 | $6,564,000 | $6,994,000 |
| Current Capital Lease Obligation | $1,371,000 | $1,467,000 | $1,097,000 | $1,029,000 |
| Current Accrued Expenses | $34,123,000 | $37,595,000 | $51,933,000 | $36,383,000 |
| Investments And Advances | $0 | $1,647,000 | $7,613,000 | $41,236,000 |
| Investmentsin Joint Venturesat Cost | $0 | $1,647,000 | $7,613,000 | $41,236,000 |
| Net PPE | $13,429,000 | $16,133,000 | $10,260,000 | $11,230,000 |
| Accumulated Depreciation | $-5,320,000 | $-4,275,000 | $-3,408,000 | $-4,312,000 |
| Gross PPE | $18,749,000 | $20,408,000 | $13,668,000 | $15,542,000 |
| Leases | $3,873,000 | $3,953,000 | $2,082,000 | $11,254,000 |
| Other Properties | $12,769,000 | $14,163,000 | $9,437,000 | $2,228,000 |
| Machinery Furniture Equipment | $2,107,000 | $2,292,000 | $2,149,000 | $2,060,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $49,000 | $82,000 | $16,000 | $560,000 |
| Work In Process | $18,338,000 | $16,095,000 | $12,057,000 | $10,562,000 |
| Foreign Currency Translation Adjustments | - | - | $-356,000 | $183,000 |
| Employee Benefits | - | - | $0 | $3,652,000 |
| Non Current Pension And Other Postretirement Benefit Plans | - | - | $0 | $3,652,000 |
| Non Current Deferred Revenue | - | - | $23,539,000 | $23,539,000 |
| Construction In Progress | - | - | $0 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-124,702,000 | $-121,902,000 | $-138,998,000 | $-239,754,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-123,835,000 | $-118,686,000 | $-138,311,000 | $-233,378,000 |
| Cash Flow From Continuing Operating Activities | $-123,835,000 | $-118,686,000 | $-138,311,000 | $-233,378,000 |
| Operating Gains Losses | $1,062,000 | $4,319,000 | $40,694,000 | $6,122,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-867,000 | $-3,216,000 | $-687,000 | $-6,376,000 |
| Investing Cash Flow | $-867,000 | $-3,216,000 | $-687,000 | $-6,673,000 |
| Cash Flow From Continuing Investing Activities | $-867,000 | $-3,216,000 | $-687,000 | $-6,673,000 |
| Net Other Investing Changes | - | - | $-210,000 | $-297,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $60,506,000 | $0 | $6,130,000 | $0 |
| Financing Cash Flow | $97,054,000 | $73,875,000 | $-897,000 | $267,394,000 |
| Cash Flow From Continuing Financing Activities | $97,054,000 | $73,875,000 | $-897,000 | $267,394,000 |
| Net Other Financing Charges | $-1,163,000 | $73,102,000 | $-122,624,000 | $218,002,000 |
| Net Common Stock Issuance | $60,506,000 | $0 | $6,130,000 | $0 |
| Common Stock Issuance | $60,506,000 | $0 | $6,130,000 | $0 |
| Repurchase Of Capital Stock | - | - | $-221,000 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Paid Supplemental Data | $15,702,000 | $15,387,000 | $10,178,000 | - |
| End Cash Position | $250,867,000 | $278,598,000 | $326,441,000 | $466,544,000 |
| Beginning Cash Position | $278,598,000 | $326,441,000 | $466,544,000 | $439,195,000 |
| Effect Of Exchange Rate Changes | $-83,000 | $184,000 | $-208,000 | $6,000 |
| Changes In Cash | $-27,648,000 | $-48,027,000 | $-139,895,000 | $27,343,000 |
| Proceeds From Stock Option Exercised | $37,711,000 | $773,000 | $0 | $778,000 |
| Net PPE Purchase And Sale | $-867,000 | $-3,216,000 | $-687,000 | $-3,430,000 |
| Purchase Of PPE | $-867,000 | $-3,216,000 | $-687,000 | $-3,430,000 |
| Change In Working Capital | $3,826,000 | $44,271,000 | $-48,725,000 | $-15,710,000 |
| Change In Other Current Liabilities | $-8,883,000 | $5,675,000 | $-1,203,000 | $12,518,000 |
| Change In Other Current Assets | $-1,936,000 | $7,489,000 | $-11,674,000 | $-6,356,000 |
| Change In Payables And Accrued Expense | $13,602,000 | $-10,970,000 | $16,556,000 | $19,316,000 |
| Change In Accrued Expense | $11,140,000 | $-14,143,000 | $16,246,000 | $12,518,000 |
| Change In Payable | $2,462,000 | $3,173,000 | $310,000 | $6,798,000 |
| Change In Account Payable | $2,462,000 | $3,173,000 | $310,000 | $6,798,000 |
| Change In Inventory | $-3,728,000 | $-5,712,000 | $-9,651,000 | $-3,022,000 |
| Change In Receivables | $4,771,000 | $47,789,000 | $-42,753,000 | $-30,218,000 |
| Changes In Account Receivables | $4,771,000 | $47,789,000 | $-42,753,000 | $-30,218,000 |
| Other Non Cash Items | $17,761,000 | $17,303,000 | $-25,406,000 | $-17,055,000 |
| Stock Based Compensation | $6,568,000 | $13,495,000 | $49,322,000 | $60,480,000 |
| Asset Impairment Charge | $1,518,000 | $1,608,000 | $2,165,000 | $-8,100,000 |
| Deferred Tax | $0 | $37,104,000 | $-1,621,000 | $-26,049,000 |
| Deferred Income Tax | $0 | $37,104,000 | $-1,621,000 | $-26,049,000 |
| Depreciation Amortization Depletion | $3,276,000 | $3,267,000 | $2,388,000 | $2,630,000 |
| Depreciation And Amortization | $3,276,000 | $3,267,000 | $2,388,000 | $2,630,000 |
| Depreciation | $3,276,000 | $3,267,000 | $2,388,000 | $2,501,000 |
| Pension And Employee Benefit Expense | $-186,000 | $-712,000 | $0 | $-365,000 |
| Earnings Losses From Equity Investments | $1,544,000 | $5,528,000 | $10,084,000 | $6,672,000 |
| Gain Loss On Investment Securities | $-296,000 | $-497,000 | $-11,504,000 | $-34,893,000 |
| Net Income From Continuing Operations | $-157,846,000 | $-240,053,000 | $-157,128,000 | $-230,026,000 |
| Issuance Of Debt | - | $0 | $115,597,000 | $49,591,000 |
| Net Issuance Payments Of Debt | - | $0 | $115,597,000 | $48,614,000 |
| Net Long Term Debt Issuance | - | $0 | $115,597,000 | $48,614,000 |
| Long Term Debt Issuance | - | $0 | $115,597,000 | $49,591,000 |
| Repayment Of Debt | - | - | $-1,011,000 | $-977,000 |
| Common Stock Payments | - | - | $-221,000 | $0 |
| Long Term Debt Payments | - | - | $-1,011,000 | $-977,000 |
| Net Intangibles Purchase And Sale | - | - | $-1,721,000 | $-2,946,000 |
| Purchase Of Intangibles | - | - | $-1,721,000 | $-2,946,000 |
| Taxes Refund Paid | - | - | $-13,473,000 | $-671,000 |
| Interest Received Cfo | - | - | $2,139,000 | $281,000 |
| Interest Paid Cfo | - | - | $-10,370,000 | $-5,280,000 |
| Change In Other Working Capital | - | - | $1,848,000 | $4,570,000 |
| Amortization Cash Flow | - | - | $118,000 | $129,000 |
| Amortization Of Intangibles | - | - | $118,000 | $129,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | $-107,000 | $-185,000 |